Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver MeetingGlobeNewsWire • 11/20/24
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver DiseasesGlobeNewsWire • 11/13/24
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative ColitisGlobeNewsWire • 07/16/24
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel DiseaseGlobeNewsWire • 05/21/24
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to PlaceboGlobeNewsWire • 04/15/24
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis CongressGlobeNewsWire • 01/25/24
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis CongressGlobeNewsWire • 01/09/24
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and PlanGlobeNewsWire • 11/13/23
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 DataGlobeNewsWire • 08/23/23
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug CandidatesGlobeNewsWire • 11/15/22
Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting PatentsGlobeNewsWire • 03/01/22
Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 02/18/22